Renal and metabolic effects of semaglutide plus canagliflozin vs canagliflozin alone in type 2 diabetic nephropathy

doi:10.4239/wjd.v17.i2.112867

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 2

This Article

(41)

(60)

(0)

(16)

(1)

(907)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Diabetes. Feb 15, 2026; 17(2): 112867
Published online Feb 15, 2026. doi: 10.4239/wjd.v17.i2.112867

Table 2 Comparison of renal function between two groups of patients before and after treatment

Parameter	Time	CM group (n = 107)	CSCT group (n = 104)	t	P value
Serum creatinine (mg/dL)	Baseline	1.04 ± 0.32	1.04 ± 0.29	0.122	0.903
	6 months	1.05 ± 0.35	1.06 ± 0.31	0.265	0.791
GFR (mL/minute/1.73 m²)	Baseline	50.83 ± 5.01	50.92 ± 5.19	0.126	0.900
	6 months	50.13 ± 4.61	50.52 ± 4.87	0.603	0.547
ACR (mg/g)	Baseline	211.51 ± 30.11	207.54 ± 30.15	0.956	0.340
	6 months	158.11 ± 28.85	145.87 ± 29.23	3.062	0.002

GFR: Glomerular filtration rate; ACR: Albumin/creatinine ratio; CM: Canagliflozin monotherapy; CSCT: Canagliflozin and semaglutide combination therapy.

Full Size Table

Citation: Miao Y, He P, Wang DY, Yan L, Cao HX, Shao FM. Renal and metabolic effects of semaglutide plus canagliflozin vs canagliflozin alone in type 2 diabetic nephropathy. World J Diabetes 2026; 17(2): 112867
URL: https://www.wjgnet.com/1948-9358/full/v17/i2/112867.htm
DOI: https://dx.doi.org/10.4239/wjd.v17.i2.112867

Miao Y, He P, Wang DY, Yan L, Cao HX, Shao FM. Renal and metabolic effects of semaglutide plus canagliflozin vs canagliflozin alone in type 2 diabetic nephropathy. World J Diabetes 2026; 17(2): 112867 [PMID: 41696107 DOI: 10.4239/wjd.v17.i2.112867]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.